Laboratory Testing Prior to Dupixent Initiation
No routine laboratory tests are required before starting dupilumab (Dupixent) for atopic dermatitis, asthma, or chronic rhinosinusitis with nasal polyposis. Analysis of over 2000 patients in phase III clinical trials demonstrated no clinically important changes in blood cells, blood chemistry, or urine chemistry that could be linked to dupilumab, leading to the conclusion that routine laboratory monitoring is unnecessary 1.
Pre-Treatment Assessment Requirements
Clinical Evaluation Only
- A thorough history and physical examination are sufficient to determine candidacy for dupilumab without mandatory laboratory screening 1.
- For chronic rhinosinusitis with nasal polyposis, confirm the presence of nasal polyps through nasal endoscopy or rhinoscopy, as this is essential for diagnosis but does not constitute laboratory testing 2, 3.
- Document baseline disease severity using validated instruments (SNOT-22, nasal polyp scores, symptom assessments) for future comparison, though these are clinical measures rather than laboratory tests 2, 4.
Optional Diagnostic Testing (Not Required for Safety)
- Specific IgE testing (skin or blood) may be performed to confirm allergic triggers in patients with rhinitis or asthma, but this is for diagnostic clarification rather than safety screening 5, 6.
- Pulmonary function testing may be indicated for patients with comorbid asthma to establish baseline lung function, but this is disease-specific assessment rather than a dupilumab safety requirement 5.
Baseline Eosinophil Considerations
Eosinophil Monitoring Is Optional
- Baseline eosinophil counts are not required before initiating dupilumab, though some clinicians obtain them for comparison if post-treatment eosinophilia develops 7.
- Among patients who had eosinophil counts checked, 11.3% developed post-treatment eosinophilia (≥1.5 × 10³/μL), but this was typically transient and rarely associated with adverse effects 7.
- Persistent eosinophilia or eosinophil-related adverse effects are rare, and most patients with eosinophilia continued to receive significant treatment benefit from dupilumab 7.
- Eosinophilic granulomatous polyangiitis occurred in only 2 of 251 patients (0.8%) in real-world use, one with eosinophilia and one with normal counts on systemic corticosteroids 7.
Common Pitfalls to Avoid
Do Not Over-Test
- Avoid ordering comprehensive metabolic panels, complete blood counts, or liver function tests as routine pre-treatment screening for dupilumab, as these have not demonstrated clinical utility 1.
- Do not delay treatment initiation while waiting for unnecessary laboratory results, as dupilumab has an excellent safety profile that does not require laboratory monitoring 1.
Distinguish from Other Biologics
- Do not confuse dupilumab's safety profile with other immunosuppressive therapies that require routine laboratory monitoring (such as methotrexate or azathioprine) 1.
- Unlike systemic corticosteroids or traditional immunosuppressants, dupilumab specifically targets IL-4 and IL-13 signaling without broad immunosuppression, eliminating the need for safety monitoring labs 1.
Disease-Specific vs. Drug-Specific Testing
- Distinguish between tests needed to diagnose the underlying condition (nasal endoscopy for polyps, CT scans for sinusitis severity) and tests needed for drug safety—only the former are necessary 2, 3, 4.
- Lund-Mackay CT scores and nasal polyp scores are useful for documenting baseline disease severity and treatment response but are not safety requirements 4.
Post-Treatment Monitoring
No Routine Laboratory Surveillance Required
- Ongoing laboratory monitoring during dupilumab treatment is not necessary based on the safety data from clinical trials 1.
- If eosinophilia develops during treatment, it typically resolves spontaneously and does not require treatment discontinuation in most cases 7.
- Continue dupilumab despite eosinophilia if the patient is deriving clinical benefit, as treatment efficacy is maintained even in patients with elevated eosinophil counts 7.